INNA KIGEL: Open Payments
NPI 1235210956 · KEW GARDENS, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,557 in 81 payments from 15 companies in 2025. Trend: 2023 $2,406 · 2024 $2,045 · 2025 $1,557
Food & beverage: $1,557
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 18 | $250 |
| AstraZeneca Pharmaceuticals LP | 10 | $233 |
| ABBVIE INC. | 11 | $227 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $198 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $195 |
| Novo Nordisk Inc | 5 | $126 |
| Gilead Sciences, Inc. | 4 | $81 |
| Sumitomo Pharma America, Inc. | 2 | $48 |
| Lilly USA, LLC | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
Products named: TRELEGY ELLIPTA, JARDIANCE, XIFAXAN, AIRSUPRA, FARXIGA, CREON, QULIPTA, Ozempic.
Industry payments across NY — which companies pay providers there.
